Endoscopy 2013; 45(12): 1039-1046
DOI: 10.1055/s-0033-1344794
Review
© Georg Thieme Verlag KG Stuttgart · New York

Updating the management of patients with rectal neuroendocrine tumors

Louis de Mestier
1  Department of Hepatogastroenterology and Digestive Oncology, University Hospital Robert-Debré, Reims, France
,
Hedia Brixi
1  Department of Hepatogastroenterology and Digestive Oncology, University Hospital Robert-Debré, Reims, France
,
Rodica Gincul
2  Department of Hepatogastroenterology, Hospital Edouard Herriot, Lyon, France
,
Thierry Ponchon
2  Department of Hepatogastroenterology, Hospital Edouard Herriot, Lyon, France
,
Guillaume Cadiot
1  Department of Hepatogastroenterology and Digestive Oncology, University Hospital Robert-Debré, Reims, France
› Author Affiliations
Further Information

Publication History

submitted 30 January 2013

accepted after revision 11 July 2013

Publication Date:
25 October 2013 (online)

Rectal neuroendocrine tumors (NETs) account for approximately one-third of all digestive NETs, with an increasing incidence and good overall prognosis. Although recent guidelines have been published, endoscopic techniques have expanded substantially and the most recent reports should be taken into account for clinical practice. The objectives of this report were to review the latest advances on prognosis, pre-interventional explorations, treatment – with particular focus on endoscopy – and surveillance of well-differentiated rectal NETs, excluding poorly differentiated and metastatic tumors.